BRPI0607084A2 - uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto - Google Patents

uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto

Info

Publication number
BRPI0607084A2
BRPI0607084A2 BRPI0607084-1A BRPI0607084A BRPI0607084A2 BR PI0607084 A2 BRPI0607084 A2 BR PI0607084A2 BR PI0607084 A BRPI0607084 A BR PI0607084A BR PI0607084 A2 BRPI0607084 A2 BR PI0607084A2
Authority
BR
Brazil
Prior art keywords
compound
composition
same
deoxy
deoxyprostaglandin
Prior art date
Application number
BRPI0607084-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of BRPI0607084A2 publication Critical patent/BRPI0607084A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0607084-1A 2005-01-27 2006-01-26 uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto BRPI0607084A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64700805P 2005-01-27 2005-01-27
PCT/JP2006/301704 WO2006080549A2 (en) 2005-01-27 2006-01-26 Method and composition for treating central nervous system disorders

Publications (1)

Publication Number Publication Date
BRPI0607084A2 true BRPI0607084A2 (pt) 2009-08-04

Family

ID=36740907

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607084-1A BRPI0607084A2 (pt) 2005-01-27 2006-01-26 uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto

Country Status (19)

Country Link
US (2) US8202909B2 (enExample)
EP (2) EP2332545A1 (enExample)
JP (1) JP5147404B2 (enExample)
KR (1) KR101354771B1 (enExample)
CN (1) CN101146541B (enExample)
AR (1) AR055846A1 (enExample)
AU (1) AU2006209072B2 (enExample)
BR (1) BRPI0607084A2 (enExample)
CA (1) CA2595898C (enExample)
DK (1) DK1841433T3 (enExample)
ES (1) ES2375082T3 (enExample)
IL (1) IL184578A (enExample)
NO (1) NO340257B1 (enExample)
NZ (1) NZ556710A (enExample)
PL (1) PL1841433T3 (enExample)
PT (1) PT1841433E (enExample)
RU (1) RU2440338C2 (enExample)
TW (1) TWI384988B (enExample)
WO (1) WO2006080549A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
WO2008108322A2 (en) * 2007-02-27 2008-09-12 Sucampo Ag Composition and method for protecting mitochondria
CN101808623B (zh) * 2007-07-19 2013-08-14 株式会社·R-技术上野 包含11-脱氧-前列腺素化合物的药物组合物和使该化合物稳定化的方法
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US9084815B2 (en) 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
IN2013MN00733A (enExample) * 2010-10-15 2015-06-12 Scinopharm Kunshan Biochemical Technology Co Ltd
JP6023082B2 (ja) * 2011-01-24 2016-11-09 インセプタム リサーチ アンド セラピューティクス，インク． 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物
AU2012246999A1 (en) * 2011-04-19 2013-10-17 Sucampo Ag Method for modulating cytokine activity
CA2842455A1 (en) * 2011-08-05 2013-02-14 Sucampo Ag Method for treating schizophrenia
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
JP6348229B2 (ja) * 2014-10-21 2018-06-27 ユニバーシタット デ レス イレス バレアレス ヒドロキシ−トリグリセリドの合成方法、および疾患の予防および処置のためのその使用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1120243A (en) 1970-03-09 1968-07-17 Samuelsson Bengt Improvements in or relating to unsaturated carboxylic acid derivatives and the manufacture thereof
BE786215A (fr) 1971-07-14 1973-01-15 American Cyanamid Co Nouveaux composes apparentes aux prostaglandines naturelles et procedesde leur preparation
ZA764727B (en) * 1975-09-02 1977-07-27 Upjohn Co Prostanoic acid derivatives
SU845774A3 (ru) 1976-04-20 1981-07-07 Фармиталия Карло Эрба С.П.А. (Фирма) Способ получени 13,14-дегидро-11-дЕзОКСипРОСТАглАНдиНОВ
US4131738A (en) * 1977-07-05 1978-12-26 The Upjohn Company 6-Hydroxy-PGE1 compounds
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
DK0444844T3 (da) 1990-02-26 1995-04-03 R Tech Ueno Ltd Hidtil ukendte 15-dehydroxy-16-oxoprostaglandiner
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
JPH04187637A (ja) 1990-11-21 1992-07-06 Ueno Seiyaku Oyo Kenkyusho:Kk 記憶改善剤
JPH07113012B2 (ja) 1991-01-29 1995-12-06 株式会社アールテック・ウエノ 新規１５−ケト−プロスタグランジン類
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
DK0978284T3 (da) * 1997-11-28 2008-10-27 Sucampo Ag Anvendelse af 15-keto-prostaglandin-E-forbindelser som endothelinantagonister
JP3703004B2 (ja) 1998-07-15 2005-10-05 小野薬品工業株式会社 ５−チア−ω−置換フェニル−プロスタグランジンＥ誘導体
AU3713600A (en) * 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
TWI284535B (en) * 2000-03-24 2007-08-01 Sucampo Ag Apoptosis inhibitor
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
CN1214794C (zh) 2003-09-08 2005-08-17 秦正红 前列腺素a1在制备治疗脑缺血性中风疾病的药物中的用途

Also Published As

Publication number Publication date
PL1841433T3 (pl) 2012-07-31
EP1841433A2 (en) 2007-10-10
NO340257B1 (no) 2017-03-27
US20120225938A1 (en) 2012-09-06
RU2440338C2 (ru) 2012-01-20
CA2595898A1 (en) 2006-08-03
KR20070107065A (ko) 2007-11-06
US8202909B2 (en) 2012-06-19
NZ556710A (en) 2010-08-27
NO20074332L (no) 2007-10-17
ES2375082T3 (es) 2012-02-24
WO2006080549A3 (en) 2007-07-05
CN101146541A (zh) 2008-03-19
US20060194880A1 (en) 2006-08-31
EP1841433B1 (en) 2011-11-30
TW200642690A (en) 2006-12-16
DK1841433T3 (da) 2012-01-16
KR101354771B1 (ko) 2014-01-22
JP2008528440A (ja) 2008-07-31
AR055846A1 (es) 2007-09-12
HK1118716A1 (en) 2009-02-20
AU2006209072B2 (en) 2011-02-24
EP2332545A1 (en) 2011-06-15
JP5147404B2 (ja) 2013-02-20
AU2006209072A1 (en) 2006-08-03
TWI384988B (zh) 2013-02-11
WO2006080549A2 (en) 2006-08-03
PT1841433E (pt) 2012-02-01
CN101146541B (zh) 2012-04-11
IL184578A0 (en) 2007-10-31
CA2595898C (en) 2015-04-28
RU2007132081A (ru) 2009-03-10
IL184578A (en) 2015-02-26

Similar Documents

Publication Publication Date Title
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
BRPI0508098A (pt) compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
IL195030A (en) Dpp iv inhibitor formulations
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CR20110206A (es) Método de uso de una sepa de bacillus subtilis para mejorar la salud de animales
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
EA201791850A1 (ru) Борсодержащие малые молекулы
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
CO6362020A2 (es) Mutantes fgf21 y uso de los mismos
BRPI0606727A (pt) terapia de combinação para o tratamento de diabetes e condições relacionadas com ele e para o tratamento de condições melhoradas através de aumento no nìvel de glp-1 no sangue
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0920261A8 (pt) Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
BRPI0509207A (pt) moduladores canabinóides de tetraidro-indazol
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
CL2008002247A1 (es) Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros.
BR112014009785A8 (pt) método para tratar ou reduzir efp
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements